Oncology

First Phase III results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy in previously treated locally advanced or metastatic disease

Longest survival follow-up reported to date for a Phase III trial in this setting

As a hematologist, your patients trust you with their lives.